Beilu Pharma(SZ:300016)2025-05-15 07:04Financial Performance - In Q1 2025, the company achieved revenue of 282.68 million CNY, a year-on-year increase of 36.23% [1] - Net profit attributable to shareholders was 14.54 million CNY, up 26.13% year-on-year [1] - Net profit excluding non-recurring items reached 13.09 million CNY, reflecting a 14.34% increase year-on-year [1] Growth Drivers - The chemical generic drug segment capitalized on national procurement policies, expanding market share and sales [1] - The traditional Chinese medicine segment achieved rapid integration and expansion through acquisitions, enhancing product pipelines [2] - International market expansion has shown results, with continuous growth in export business [2] Market Strategy - The company aims to increase domestic market share while actively participating in procurement and promoting other products [3] - New product development and market entry will be accelerated to enhance competitiveness [3] - The company will leverage EU GMP and Brazil GMP certifications to boost international market contributions [3] Acquisition Progress - The integration of Tianyuan Pharmaceutical is progressing smoothly across production, marketing, finance, and supply chain management [4] - The company is focusing on fine management and sustainable development of Tianyuan Pharmaceutical [4] Overseas Revenue - In the reporting period, overseas revenue reached 132.16 million CNY, a year-on-year increase of 15.02% [6] - The company successfully exported contrast agents and raw materials to markets in South America, Africa, and Asia [5] R&D Developments - R&D investment for the period was 69.24 million CNY, a decrease of 43.40% year-on-year due to a stabilization phase in project initiation [7] - The company has 12 projects under review and 23 new projects initiated, totaling 35 projects [7] - Recent approvals include various formulations and specifications for contrast agents and other medications [7] Production Base Development - The construction of the Bozhou production base is progressing, with the first phase expected to begin trial production within the year [8] - The base will enhance production capacity for various dosage forms, supporting future strategic expansions in traditional and chemical medicine [8]